Companies › Arcutis Biotherapeutics
2 active drug programs in 13 registered trials: 8 Phase 2, 2 Phase 1, 2 Phase 3, 1 Phase 4; Immunology, Oncology, Other, Psychiatry; next expected readout Apr 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Roflumilast Phosphodiesterase 4 inhibitor | PDE4A, PDE4D, PDE4B, PDE4C | Phase 3 | Atopic Dermatitis; Chronic Plaque Psoriasis; Depressive Disorder, Major; Fragile X Syndrome … | Apr 2028 |
| ARQ-234 | – | Phase 1 | Atopic Dermatitis (AD) | Apr 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05418049 | Roflumilast | Phase 2 | Fragile X Syndrome | Other | Oct 2025 |
| NCT07233291 | Roflumilast | Phase 2 | Psoriasis (PsO) | Immunology | Feb 2026 |
| NCT07105254 | Roflumilast | Phase 2 | Non-segmental Vitiligo | Immunology | May 2026 |
| NCT07297602 | Roflumilast | Phase 2 | Atopic Dermatitis | Immunology | May 2026 |
| NCT07632846 | Roflumilast | Phase 2 | Rheumatoid Arthritis | Immunology | Dec 2026 |
| NCT06860958 | Roflumilast | Phase 3 | Depressive Disorder, Major | Psychiatry | Mar 2027 |
| NCT06977711 | Roflumilast | Phase 1 | Diffuse Large B-cell Lymphoma | Oncology | Apr 2027 |
| NCT07566351 | Roflumilast | Phase 2 | Rheumatoid Arthritis | Immunology | Jun 2027 |
| NCT07725822 | Roflumilast | Phase 4 | Chronic Plaque Psoriasis | Immunology | Jul 2027 |
| NCT07689188 | Roflumilast | Phase 2 | Hidradenitis Suppurativa (HS) | Immunology | Mar 2028 |
| NCT07453602 | ARQ-234 | Phase 1 | Atopic Dermatitis (AD) | Immunology | Apr 2028 |
| NCT07916480 | Roflumilast | Phase 3 | Atopic Dermatitis | Immunology | Apr 2028 |
| NCT07263230 | Roflumilast | Phase 2 | Hidradenitis Suppurativa (HS) | Immunology | Aug 2028 |
Cash and short-term investments of $259m on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 7 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Ganzhou Hemay Pharmaceutical Palisade Bio Integrative Skin Science and Research BioCryst Pharmaceuticals Pacira Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.